Frontlight ResearchEarly access
Active, not recruitingEarly phase 1
Vaccine Pandemic Preparedness Through Airway Immunology Characterization
Key facts
- Who runs it
- Copenhagen Respiratory Research
- Where
- Denmark and United Kingdom2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Early phase 1
- People taking part
- 60 people, planned
- Started
- 19 May 2025
- Expected to end
- 31 Oct 2032
- Type of study
- Interventional, 2 groups
- Treatments tested
- Vaxigripetra
- Flumist
- Record updated
- 6 November 2026
Who can take part
- Age
- 18 years to 49 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Healthy individuals (Charlson´s co-morbidity index :0, and investigator judged as healthy)
- Age: 18-49 years
- Total IgG levels in normal range (discretion of investigator according to local lab)
- Total IgA levels (discretion of investigator according to local lab)
- Undetectable HAI titres to the H3N2 component of the vaccines*
- Normal CD4+ and CD8+ T-cell and normal B-cell counts
- Reference levels from ISO-15189 accredited T-, B- and NK-cell count routine analyses will be applied; If <20% of the first 100 screened persons apply to this criterion, this will be changed to a specific cut off based on the lowest quartile level of HAI titres to the H3N2 component of these 100 screened persons
Who cannot take part
- Any allergies to components of or contraindication for Vaxigriptetra® or Flumist® incl. previous severe adverse reactions to influenza vaccinations or components of the vaccines
- Use of immunosuppressive drugs* within the past 6 months or who are currently using them
- Have an acute illness, including an oral temperature ≥ 38°C, within 3 days prior to vaccination
- Have received any vaccines, including live-attenuated vaccines within 4 weeks before inclusion, or plan receipt of such vaccines within 30 days following the inclusion
- Inability to provide written informed consent; defined as: Azathioprin, methotrexate, cyclophosphamide, basiliximab, belimumab, anifrolumab, alemtuzumab, rituximab, mycophenolat, calcineurin inhibitors (ciclosporin, voclosporin and tacrolimus), mTOR inhibitors (everolimus and sirolimus), prednisolone (or any corticosteroid in doses above the equivalent of 5 mg prednisolone), TNF-α inhibitors (such as infliximab), anti-thymocyte globulin
- Any known malignant neoplasm within 5 years (except basal carcinoma of the skin)
- Severe mental illness or linguistic issues which significantly impedes cooperation
- Laboratory-confirmed influenza infection during the past year documented by a positive PCR test in the Danish Microbiological database or anamnestic reported influenza infection in the same period
- HIV, HBV, HCV laboratory confirmed active infection at screening visit
- Active smoker
- BMI > 35 kg/m2
- Women of childbearing potential not using safe contraception, or who are pregnant, or breast-feeding
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study aims to compare the effectiveness of live attenuated influenza vaccines (LAIV) and intramuscular-inactivated vaccines (IIV) in healthy individuals aged 18-49. It will investigate cellular and humoral responses, identify immunological markers for targeted vaccine improvement, and establish a collaborative platform for accelerated immunological and clinical vaccine research.
The 2 groups in the trial
- VaxigripetraTreatment being tested
This arm will receive 1 dose of 0.5 mL Vaxigripetra (intra-muscular injection) and 1 dose of 0.2 mL placebo (nasal, 1 spray in each nostril).
- FlumistTreatment being tested
1 dose of 0.2 mL Flumist (nasal, 1 spray in each nostril) and 1 dose of 0.5 mL placebo (intra-muscular injection).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- In-depth Immunological Analysis of Airway Immunity Following Nasal Live Attenuated and Intramuscular Influenza Vaccine
- Record updated
- 6 November 2026